Keep pulling the thread on Vasant Narasimhan.
Under CEO Vasant Narasimhan, Novartis underwent a multi-year strategic transformation to become a pure-play innovative medicines company by divesting non-core assets.
As part of its strategic refocusing, Novartis spun off its Alcon and Sandoz businesses and sold its stake in Roche.
Novartis's market capitalization is $235 billion, and the businesses it spun off represent an additional market capitalization of almost $100 billion.
Novartis believes that using cell therapy to reset the immune system could turn back the clock on severe immunological diseases by 15 or 20 years.
Novartis is developing RNA therapeutics that could replace daily medications with injections administered every six months or once a year.
Novartis is pioneering radioligand therapy, a technique that links a radioactive particle to a drug to target and eliminate tumors directly.
Novartis is partnering with Isomorphic Labs, a Google DeepMind company, to use AI to design novel drug candidates for previously 'undruggable' targets.
The European pharmaceutical market is half the size of the U.S. market, or less, and is not growing, despite Europe having a slightly larger population.
China is now the second-largest pharmaceutical market in the world and is growing at a double-digit rate.
Approximately 30-40% of new drugs are not launched in Europe, limiting patient access primarily to the US, China, and Japan.
To adapt to geopolitical shifts, Novartis is ensuring it has dedicated manufacturing capacity in the U.S. for the U.S. market and in China for the Chinese market.
China's pace of clinical trial startup and patient recruitment is now the fastest in the world, outpacing both Europe and the United States.